PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis

Abstract Background The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia. However, evidence of the optimal PCSK9 agents targeting PCSK9 for secondary prevention in patients with high-risk of cardiovascular ev...

Full description

Bibliographic Details
Main Authors: Xing Wang, Dingke Wen, Yuqi Chen, Lu Ma, Chao You
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Cardiovascular Diabetology
Subjects:
PCSK9 inhibitors
Secondary prevention
Cardiovascular disease
Atherosclerosis
Online Access:https://doi.org/10.1186/s12933-022-01542-4

Internet

https://doi.org/10.1186/s12933-022-01542-4

Similar Items